Results 201 to 210 of about 162,707 (386)

CD20+FCRL4+ B Cells Activate CD8+ T Cells via MHC‐I Restriction in Nasopharyngeal Carcinoma Anti‐Tumor Immunity

open access: yesAdvanced Science, EarlyView.
CD20⁺FCRL4⁺ B cells in nasopharyngeal carcinoma actively cross‐present exogenous tumor antigens via MHC‐I, enhancing CD8⁺ T‐cell activation, memory formation, and cytotoxicity. IFNγ‐driven WDFY4 upregulation facilitates this process. These findings reveal an unconventional B‐cell–mediated antitumor mechanism and indicate potential relevance to ...
Benjian Zhang   +17 more
wiley   +1 more source

Intensity modulated radiation therapy vs 3D conformal radiotherapy in the radical treatment prostate cancer: Analysis of acute and late toxicity [PDF]

open access: diamond, 2018
Slavica Marić   +6 more
openalex   +1 more source

PRDM1+ Malignant Cells Mediate an Immunosuppressive Landscape and Resistance to Neoadjuvant Chemoradiotherapy and Immunotherapy in Esophageal Squamous Cell Carcinoma

open access: yesAdvanced Science, EarlyView.
Integrated scRNA‐seq, scTCR‐seq analysis, and functional assays identify PRDM1+ malignant epithelial cells with hyper lipid peroxidation characteristics that demonstrate reduced responsiveness to the nICRT treatment. Principal factor PRDM1 activates cysteine metabolism genes to modulate lipid peroxidation (an intrinsic cellular pathway related to ...
Dijian Shen   +12 more
wiley   +1 more source

T4/N2 classification nasopharyngeal carcinoma benefit from concurrent chemotherapy in the era of intensity-modulated radiotherapy

open access: diamond, 2016
Ruifei Xie   +8 more
openalex   +2 more sources

Targeting Lactate and Lactylation in Cancer Metabolism and Immunotherapy

open access: yesAdvanced Science, EarlyView.
Lactate, once deemed a metabolic waste, emerges as a central regulator of cancer progression. This review elucidates how lactate and its epigenetic derivative, protein lactylation, orchestrate tumor metabolism, immune suppression, and therapeutic resistance.
Jiajing Gong   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy